Project Grant R56DE034087
Award Date
8/1/24
Completion Date
7/31/25
Dollars Obligated
$598K
Federal Agency
National Institute of Dental and Craniofacial Research
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research to improve understanding of oral cancer pain mechanisms. The $162,743 award, effective March 10, 2025 through February 28, 2030, will enable New York University (NYU) to: Develop and validate new methods to measure pressure and stretch sensitivity in oral cancer patients, providing novel insights into...
This federal Project Grant award, valued at $274,100.00 and funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to investigate the role of Protease-Activated Receptor 2 (PAR2) in oral cancer pain. The key objectives are to: 1) Determine the impact of oral cancer on PAR2 trafficking and signaling in trigeminal neurons, and 2) Develop nanoparticles to target PAR2 located at specific cellular...
This $390,000 Project Grant award under the National Institute of Dental and Craniofacial Research's (NIDCR) Oral Diseases and Disorders Research program (CFDA 93.121) supports research at the Medical College of Wisconsin, Inc. to leverage single-cell co-culture and gene expression profiling techniques for identifying tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The key objectives are to: 1) Use a high-throughput single-cell co-culture system to isolate and identify...
This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
This $550,296 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop a multimodal imaging diagnostic platform to improve risk assessment of precancerous oral lesions. The key products and services to be delivered under this grant include: Development of machine learning and deep learning models using Fourier transform infrared (FTIR) imaging techniques for risk...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $808,264 to uncover the mechanisms governing intracellular delivery of small interfering RNA (siRNA) complexes via cell-penetrating peptide carriers, with a focus on targeting migrating and invading oral cancer cells. The research aims to elucidate how the RD3AD peptide carrier facilitates siRNA uptake through...
This federal Project Grant award, valued at $1,880,856.00 and awarded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program, supports research on the role of the oral glucocorticoid system in oral carcinogenesis and the effects of the chemopreventive agent gallic acid on glucocorticoid metabolism. The research, conducted by The Ohio State University, aims to determine the mechanistic impact of the oral...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $799,270 to Keraceuticals, Inc. to develop novel 1,3-thiourea anticancer compounds for the treatment of oral squamous cell carcinoma (OSCC). The key products and services under this award are: Formulating the lead compound CIDD99 for oral and/or intravenous administration, and rapidly assessing the pharmacokinetics and...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $2,805,385 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Oregon Health & Science University (OHSU). The grant's objective is to define T cell-based mechanisms underlying oral mucosal immune-related adverse events (irAEs) caused by anti-PD-1 cancer immunotherapy. The research aims to determine the functional significance of regulatory T cells (Tregs) and Th17 cells in oral...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), will fund research to define oral squamous cell carcinoma (OSCC)-associated microbiome and metabolome signatures and determine if microbiota transfer from OSCC patients to mouse models promotes tumorigenesis. The $234,000 award to the University of Colorado-Denver will extend previous studies on the role of the human...